Compare H World Group Limited American Depositary Shares (HTHT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H World Group Limited American Depositary Shares vs Travere Therapeutics Inc. Common Stock — how do they compare? H World Group Limited American Depositary Shares trades at $44.2 (market cap $14.00B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: H World Group Limited American Depositary Shares is far larger — about 2.8× Travere Therapeutics Inc. Common Stock's market cap, and H World Group Limited American Depositary Shares pays a 4.91% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold H World Group Limited American Depositary Shares for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| HTHT | TVTX | |
|---|---|---|
Market Cap | $14.00B | $5.02B |
Volume | 1,318,511 | 2,060,842 |
Sector | Consumer Cyclical | Health |
52-Week High | $56.06 | $67.52 |
52-Week Low | $36.99 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $16.79B | $5.15B |
Dividend Yield | 4.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTHT trades at $44.17, down 0.85% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.78 exceeding the $0.74 estimate. Revenue for 2025 was $25.31 billion, with a net income margin of 18.93% and robust ROE of 38.39%. Positive news highlights the asset-light model's margin improvement and a recent CNY bond offering.
The outlook remains positive with a consensus price target of $50.56, implying 14.5% upside, supported by earnings momentum and operational efficiency. Key risks include market saturation in China and reliance on domestic growth. Analyst sentiment is bullish with 11 buy ratings out of 19, though valuation multiples like a P/E of 31.46 warrant monitoring.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About H World Group Limited American Depositary Shares
H World Group operates hotels through leased and owned, managed franchise, and franchise models. Its brands include HanTing, JI Hotel, Orange Hotel, and Steigenberger Hotels & Resorts.
Read more on HTHT →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
